Scope Statement

Given that science is typically 5-10 years in advance of regulation, and that nanoscience and nanotechnology development is outpacing nanomaterial health risk assessment information, there is a strong likelihood that many companies working with nanomaterials are not aware of the potential for unique risks from nanomaterials, and especially from nanopowders. Thus, in parallel with the development of strategies for prediction of toxicity and biological impacts, for assessment of exposure to nanomaterials, and for risk assessment, it is essential that appropriate risk management and risk control strategies be identified that can be implemented in laboratories and small or large companies. Through participation in active exchange by knowledgeable scientists, industrial hygienists and related occupational health and safety professionals, development of best practices will emerge that can be widely shared and used without requiring a high degree of expertise in nanosafety risk assessment. Where gaps are identified in the fundamental risk management variables, specific training and/or research needs will be identified to improve risk management decision-making and implementation. Directed training will be required for occupational hygienists and workplace health monitors.